安罗替尼联合紫杉醇+奈达铂治疗复发宫颈癌的疗效及对患者免疫功能的影响  

Efficacy of anlotinib combined with paclitaxel+nedaplatin in the treatment of recurrent cervical cancer and its impact on immune function

作　　者：贾冬丽[1] 王慧芬[1] 张清伟[1] JIA Dongli;WANG Huifen;ZHANG Qingwei(First Department of Gynecology,Luohe Central Hospital,Luohe 462000,He’nan,China)

机构地区：[1]漯河市中心医院妇科一,河南漯河462000

出　　处：《癌症进展》2025年第2期199-201,205,共4页Oncology Progress

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20230939)。

摘　　要：目的探讨安罗替尼联合紫杉醇+奈达铂治疗复发宫颈癌的疗效及对患者免疫功能的影响。方法依据治疗方法的不同将80例复发宫颈癌患者分为对照组39例和观察组41例,对照组患者接受紫杉醇+奈达铂治疗,观察组患者接受安罗替尼联合紫杉醇+奈达铂治疗。比较两组患者的临床疗效、T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+))水平、血管内皮生长因子(VEGF)水平、血小板衍生生长因子(PDGF)水平及不良反应发生情况。结果观察组患者疾病控制率为70.73%,高于对照组患者的48.72%,差异有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)、PDGF水平均高于本组治疗前,CD8^(+)、VEGF水平均低于本组治疗前,观察组患者CD3^(+)、CD4^(+)、PDGF水平均高于对照组,CD8^(+)、VEGF水平均低于对照组,差异均有统计学意义(P﹤0.05)。两组患者血小板减少、中性粒细胞减少、恶心呕吐、白细胞减少发生率比较,差异均无统计学意义(P﹥0.05)。结论安罗替尼联合紫杉醇+奈达铂治疗复发宫颈癌的疗效显著,可改善患者的免疫功能,调节血清VEGF、PDGF水平,且安全性较高。Objective To investigate the efficacy of anlotinib combined with paclitaxel+nedaplatin in the treatment of recurrent cervical cancer and its impact on immune function.Method According to different treatment methods,80 patients with recurrent cervical cancer were divided into control group(n=39)and observation group(n=41).Patients in control group received paclitaxel^(+)nedaplatin treatment,while patients in observation group received anlotinib combined with paclitaxel^(+)nedaplatin treatment.The clinical efficacy,T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+))levels,vascular endothelial growth factor(VEGF)level,platelet-derived growth factor(PDGF)level,and incidence of adverse reactions were compared between the two groups.Result The disease control rate in observation group was 70.73%,which was higher than 48.72%in control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CD3^(+),CD4^(+)and PDGF in both groups were higher than those before treatment,while the levels of CD8^(+)and VEGF were lower than those before treatment,the levels of CD3^(+),CD4^(+)and PDGF in observation group were higher than those in control group,while the levels of CD8^(+)and VEGF were lower than those in control group,and the differences were statistically significant(P<0.05).There were no statistically significant differences in the incidences of thrombocytopenia,neutropenia,nausea and vomiting,and leukopenia between the two groups(P>0.05).Conclusion The anlotinib combined with paclitaxel^(+)nedaplatin has a significant therapeutic effect on recurrent cervical cancer,which can improve immune function,regulate serum VEGF and PDGF levels,and is relatively safe.

关 键 词：宫颈癌 化疗 安罗替尼 T淋巴细胞亚群 

分 类 号：R737.33[医药卫生—肿瘤]